Direct endoscopic necrosectomy for the treatment of walled-off pancreatic necrosis: results from a multicenter U.S. series - 11/08/11
Résumé |
Background |
Direct endoscopic necrosectomy (DEN) for treatment of walled-off pancreatic necrosis (WOPN) has been performed as an alternative to operative or percutaneous therapy.
Objective |
To report the largest combined experience of DEN performed for WOPN.
Design |
Retrospective chart review.
Setting |
Six U.S. tertiary medical centers.
Patients |
A total of 104 patients with a history of acute pancreatitis and symptomatic WOPN since 2003.
Interventions |
DEN for WOPN.
Main Outcome Measurements |
Resolution or near-resolution of WOPN without the need for surgical or percutaneous intervention and procedural complications.
Results |
Successful resolution was achieved in 95 of 104 patients (91%). Of the patients in whom it failed, 5 died during follow-up before resolution, 2 underwent operative drainage for persistent WOPN, 1 required surgery for massive bleeding on fistula tract dilation, and 1 died periprocedurally. The mean time to resolution from the initial DEN was 4.1 months. The first débridement was performed a mean of 63 days after the initial onset of acute pancreatitis. In 73%, the entry was transgastric with median tract dilation diameter of 18 mm. The median number of procedures was 3 with 2 débridements. Complications occurred in approximately 14% and included 5 retrogastric perforations/pneumoperitoneum, which were managed nonoperatively. Univariate analysis identified a body mass index >32 as a risk factor for failed DEN.
Limitations |
Retrospective, highly specialized centers.
Conclusions |
This large, multicenter series demonstrates that transmural, minimally invasive endoscopic débridement of WOPN performed in the United States is an efficacious and reproducible technique with an acceptable safety profile.
Le texte complet de cet article est disponible en PDF.Abbreviations : BMI, DEN, WOPN
Plan
DISCLOSURE: The following authors disclosed financial relationships relevant to this publication: Dr. Gardner: consultant to Boston Scientific; Dr. Freeman: speaker for Boston Scientific and Cook Endoscopy. All other authors disclosed no financial relationships relevant to this publication. |
|
If you would like to chat with an author of this article, you may contact Dr. Baron at baron.todd@mayo.edu. |
|
See CME section; p. 798. |
Vol 73 - N° 4
P. 718-726 - avril 2011 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?